|
|
Vaccine Detail
|
TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell Vaccine |
| Vaccine Information |
- Vaccine Name: TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Immunization Route: Intradermal injection (i.d.)
- Description: GMCSF transgene directly stimulates increased expression of tumor antigen(s) and enhances dendritic cell migration to the vaccination site. TGFβ2 blockade following intracellular TGFβ2 antisense gene expression reduces production of immune inhibiting activity at the vaccine site. This vaccine integrates enhancement of an anticancer immune response concurrently with a reduction in cancer-induced immune suppression. Autologous cancer cells are harvested from patients with advanced refractory cancer, and a TGFβ2 antisense / GMCSF expression vector plasmid is constructed. The autologous cancer tissue is irradiated and electrocorporated with the vector. (NCT00684294)
|
| Host Response |
|
|
| References |
NCT00684294: Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer (Auto TAG) [https://clinicaltrials.gov/study/NCT00684294]
|
|
